Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$6.92 USD
-0.34 (-4.68%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $6.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum D VGM
Voyager Therapeutics (VYGR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.44 | $30.00 | $7.00 | 140.22% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Voyager Therapeutics comes to $17.44. The forecasts range from a low of $7.00 to a high of $30.00. The average price target represents an increase of 140.22% from the last closing price of $7.26.
Analyst Price Targets (9 )
Broker Rating
Voyager Therapeutics currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, nine are Strong Buy, representing 90% of all recommendations. A month ago, Strong Buy represented 90%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/31/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
5/14/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
5/14/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
3/26/2024 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Strong Buy |
3/7/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/29/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
1/3/2024 | Robert W. Baird & Co. | Jack K Allen | Not Available | Strong Buy |
1/2/2024 | Wells Fargo Securities | Yanan Zhu | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 10 |
Average Target Price | $17.44 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 253 |
Current Quarter EPS Est: | -0.53 |